Evidence map›Paper›PMID 31299041›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma.

Yunhui Chan, Yipeng Yu, Gang Wang, Changlin Wang, Daming Zhang, Xiaoxiong Wang, Zichun Wang, Wengang Jian, Cheng Zhang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yunhui ChanDepartment of Urology, Third Ward, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Yipeng YuDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Gang WangDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Changlin WangDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Daming ZhangDepartment of Pharmacology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Xiaoxiong WangDepartment of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Zichun WangDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Wengang JianDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Cheng ZhangDepartment of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Harbin Medical University · CNFirst Affiliated Hospital of Harbin Medical University · CN

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

BACKGROUND MicroRNA-381 (miR-381) is proven to be involved in many human tumors. Bioinformatics prediction suggests that miR-381 is decreased in renal cell carcinoma. However, its biological functions in clear-cell renal cell carcinoma (ccRCC) remain largely unknown. The present research aimed to evaluate miR-381 expression in renal cancer tissues and its effects on cell proliferation, growth, migration, and chemoresistance. MATERIAL AND METHODS Sixty pairs of ccRCC and the adjacent non-tumor specimens were collected during routine therapeutic surgery. Quantitative real-time PCR (qRT-PCR) assay was employed to examine miR-381 expression in the ccRCC tissues and the associated adjacent tissues (the normal tissues adjacent to tumor tissues). Cell transfection assay and Thiazolyl Blue Tetrazolium Bromide (MTT) assay were utilized to observe effects of miR-381 on the cell proliferation, growth, invasion, and chemoresistance in the Caki-1 cell line and 786-O cell line. Flow cytometry was used to assess cell apoptosis. Caki-1 cell and 786-O cell Xenograft BALB/c mouse models were established. RESULTS miR-381 expression was downregulated in ccRCC tissues in vivo and in cell lines in vitro. Downregulation of miR-381 promoted growth of cells and restrained the ccRCC cell apoptosis. Increased miR-381 combined with Ci and Pa suppressed the proliferation and enhanced the anti-tumor effects of Ci and Pa at tolerated concentrations in vitro. miR-381 inhibition promoted chemoresistance in vitro. CONCLUSIONS miR-381 levels were significantly downregulated in renal cancer tissues and miR-381 inhibition promoted tumor cell growth, migration, and chemoresistance.

Indexed as

AgedAged, 80 and overAnimalsApoptosisCarcinoma, Renal CellCell CycleCell Growth ProcessesCell MovementDown-RegulationDrug Resistance, NeoplasmFemaleHumansKidney NeoplasmsMaleMiceMice, Inbred BALB CMicroRNAsMIRN381 microRNA, human

Identifiers

PMID31299041
PMCPMC6642673
OpenAlexW2961660420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.